Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
Clinical trial NCT02674568 · COMPLETED
Trial details
- NCT number
- NCT02674568
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-25
- Primary completion
- 2018-10-19
- Enrollment
- 342
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.